A capsule conjugate vaccine approach to prevent diarrheal disease caused by Campylobacter jejuni

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 6, 2014, Pages 1499-1504

  Maue, Alexander C ^a   Poly, Frédéric ^a   Guerry, Patricia ^a  

^a NAVAL MEDICAL RESEARCH CENTER   (United States)

Author keywords

Campylobacter; Capsular polysaccharide; Conjugate vaccines; Diarrheal disease; GBS

Indexed keywords

BACTERIAL VACCINE; VACCINE;

BACTERIAL CAPSULE; CAMPYLOBACTER INFECTIONS; CAMPYLOBACTER JEJUNI; CLINICAL TRIAL (TOPIC); DIARRHEA; DRUG DEVELOPMENT; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; MICROBIOLOGY; TRENDS;

BACTERIAL CAPSULES; BACTERIAL VACCINES; CAMPYLOBACTER INFECTIONS; CAMPYLOBACTER JEJUNI; CLINICAL TRIALS AS TOPIC; DIARRHEA; DRUG DISCOVERY; HUMANS; VACCINES, CONJUGATE;

EID: 84905841954     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.27985     Document Type: Review

References (71)

1. Blaser MJ. Epidemiologic and clinical features of Campylobacter jejuni infections. J Infect Dis 1997; 176(Suppl 2):S103-5; PMID:9396691; http://dx.doi.org/10.1086/513780
2. WHO. The global view of campylobacteriosis: report of an expert consultation, Utrecht, Netherlands, 9-11 July 2012. Available from: http://wwwwhoint/foodsafety/publications/foodborne-disease/global-view- campylobacterosis/en/ accessed 13 January 2014 Geneva: World Health Organization 2013.
3. Riddle MS, Gutierrez RL, Verdu EF, Porter CK. The chronic gastrointestinal consequences associated with campylobacter. Curr Gastroenterol Rep 2012; 14:395-405; PMID:22864805; http://dx.doi.org/10.1007/s11894-012-0278-0
4. Coker AO, Isokpehi RD, Thomas BN, Amisu KO, Obi CL. Human campylobacteriosis in developing countries. Emerg Infect Dis 2002; 8:237-44; PMID:11927019; http://dx.doi.org/10.3201/eid0803.010233
5. Griffiths PL, Park RW. Campylobacters associated with human diarrhoeal disease. J Appl Bacteriol 1990; 69:281-301; PMID:2246137; http://dx.doi.org/10. 1111/j.1365-2672.1990.tb01519.x
6. Friedman CR, Hoekstra RM, Samuel M, Marcus R, Bender J, Shiferaw B, Reddy S, Ahuja SD, Helfrick DL, Hardnett F, et al.; Emerging Infections Program FoodNet Working Group. Risk factors for sporadic Campylobacter infection in the United States: A case-control study in FoodNet sites. Clin Infect Dis 2004; 38(Suppl 3):S285-96; PMID:15095201; http://dx.doi.org/10.1086/381598
7. Heuvelink AE, van Heerwaarden C, Zwartkruis-Nahuis A, Tilburg JJ, Bos MH, Heilmann FG, Hofhuis A, Hoekstra T, de Boer E. Two outbreaks of campylobacteriosis associated with the consumption of raw cows' milk. Int J Food Microbiol 2009; 134:70-4; PMID:19167125; http://dx.doi.org/10.1016/j. ijfoodmicro.2008.12.026
8. Jakopanec I, Borgen K, Vold L, Lund H, Forseth T, Hannula R, Nygård K. A large waterborne outbreak of campylobacteriosis in Norway: the need to focus on distribution system safety. BMC Infect Dis 2008; 8:128; PMID:18816387; http://dx.doi.org/10.1186/1471-2334-8-128
9. Beaudeau P, de Valk H, Vaillant V, Mannschott C, Tillier C, Mouly D, Ledrans M. Lessons learned from ten investigations of waterborne gastroenteritis outbreaks, France, 1998-2006. J Water Health 2008; 6:491-503; PMID:18401114; http://dx.doi.org/10.2166/wh.2008.051
10. Neimann J, Engberg J, Mølbak K, Wegener HC. A case-control study of risk factors for sporadic campylobacter infections in Denmark. Epidemiol Infect 2003; 130:353-66; PMID:12825719
11. Danis K, Di Renzi M, O'Neill W, Smyth B, McKeown P, Foley B, Tohani V, Devine M. Risk factors for sporadic Campylobacter infection: an all-Ireland case-control study. Euro Surveill 2009; 14:14; PMID:19232225
12. Gallay A, Bousquet V, Siret V, Prouzet-Mauléon V, Valk Hd, Vaillant V, Simon F, Le Strat Y, Mégraud F, Desenclos JC. Risk factors for acquiring sporadic Campylobacter infection in France: results from a national case-control study. J Infect Dis 2008; 197:1477-84; PMID:18444804; http://dx.doi.org/10.1086/587644
13. Jones TF, Scallan E, Angulo FJ. FoodNet: overview of a decade of achievement. Foodborne Pathog Dis 2007; 4:60-6; PMID:17378709; http://dx.doi.org/10.1089/fpd.2006.63
14. Riddle MS, Sanders JW, Putnam SD, Tribble DR. Incidence, etiology, and impact of diarrhea among longterm travelers (US military and similar populations): a systematic review. Am J Trop Med Hyg 2006; 74:891-900; PMID:16687698
15. Janssen R, Krogfelt KA, Cawthraw SA, van Pelt W, Wagenaar JA, Owen RJ. Host-pathogen interactions in Campylobacter infections: the host perspective. Clin Microbiol Rev 2008; 21:505-18; PMID:18625685; http://dx.doi.org/10.1128/ CMR.00055-07
16. Ang CW, Jacobs BC, Laman JD. The Guillain-Barré syndrome: a true case of molecular mimicry. Trends Immunol 2004; 25:61-6; PMID:15102364; http://dx.doi.org/10.1016/j.it.2003.12.004
17. Pope JE, Krizova A, Garg AX, Thiessen-Philbrook H, Ouimet JM. Campylobacter reactive arthritis: a systematic review. Semin Arthritis Rheum 2007; 37:48-55; PMID:17360026; http://dx.doi.org/10.1016/j.semarthrit.2006.12. 006
18. Pimentel M, Chatterjee S, Chang C, Low K, Song Y, Liu C, Morales W, Ali L, Lezcano S, Conklin J, et al. A new rat model links two contemporary theories in irritable bowel syndrome. Dig Dis Sci 2008; 53:982-9; PMID:17934822; http://dx.doi.org/10.1007/s10620-007-9977-z
19. Lee G, Pan W, Peñataro Yori P, Paredes Olortegui M, Tilley D, Gregory M, Oberhelman R, Burga R, Chavez CB, Kosek M. Symptomatic and asymptomatic Campylobacter infections associated with reduced growth in Peruvian children. PLoS Negl Trop Dis 2013; 7:e2036; PMID:23383356; http://dx.doi.org/ 10.1371/journal.pntd.0002036
20. da Silva Quetz J, Lima IF, Havt A, de Carvalho EB, Lima NL, Soares AM, Mota RM, Guerrant RL, Lima AA. Campylobacter jejuni and Campylobacter coli in children from communities in Northeastern Brazil: molecular detection and relation to nutritional status. Diagn Microbiol Infect Dis 2010; 67:220-7; PMID:20542202; http://dx.doi.org/10.1016/j.diagmicrobio.2010.02.025
21. Ang CW, De Klerk MA, Endtz HP, Jacobs BC, Laman JD, van der Meché FG, van Doorn PA. Guillain-Barré syndrome- and Miller Fisher syndrome-associated Campylobacter jejuni lipopolysaccharides induce anti-GM1 and anti-GQ1b Antibodies in rabbits. Infect Immun 2001; 69:2462-9; PMID:11254608; http://dx.doi.org/10.1128/IAI.69.4.2462-2469.2001
22. Hoffmann S, Batz MB, Morris JG Jr. Annual cost of illness and quality-adjusted life year losses in the United States due to 14 foodborne pathogens. J Food Prot 2012; 75:1292-302; PMID:22980013; http://dx.doi.org/10. 4315/0362-028X.JFP-11-417
23. Konkel ME, Babakhani F, Joens LA. Invasion-related antigens of Campylobacter jejuni. J Infect Dis 1990; 162:888-95; PMID:2401792; http://dx.doi.org/10.1093/infdis/162.4.888
24. Poly F, Ewing C, Goon S, Hickey TE, Rockabrand D, Majam G, Lee L, Phan J, Savarino NJ, Guerry P. Heterogeneity of a Campylobacter jejuni protein that is secreted through the flagella filament. Infect Immun 2007; http://dx.doi.org/10. 1128/IAI.00159-07
25. Barrero-Tobon AM, Hendrixson DR. Identification and analysis of flagellar coexpressed determinants (Feds) of Campylobacter jejuni involved in colonization. Mol Microbiol 2012; 84:352-69; PMID:22375824; http://dx.doi.org/ 10.1111/j.1365-2958.2012.08027.x
26. Christensen JE, Pacheco SA, Konkel ME. Identification of a Campylobacter jejuni-secreted protein required for maximal invasion of host cells. Mol Microbiol 2009; 73:650-62; PMID:19627497; http://dx.doi.org/10.1111/j.1365-2958. 2009.06797.x
27. Neal-McKinney JM, Konkel ME. The Campylobacter jejuni CiaC virulence protein is secreted from the flagellum and delivered to the cytosol of host cells. Front Cell Infect Microbiol 2012; 2:31; PMID:22919623; http://dx.doi.org/10.3389/fcimb.2012.00031
28. Kopecko DJ, Hu L, Zaal KJ. Campylobacter jejuni - microtubule-dependent invasion. Trends Microbiol 2001; 9:389-96; PMID:11514222; http://dx.doi.org/10. 1016/S0966-842X(01)02107-2
29. Parkhill J, Wren BW, Mungall K, Ketley JM, Churcher C, Basham D, Chillingworth T, Davies RM, Feltwell T, Holroyd S, et al. The genome sequence of the food-borne pathogen Campylobacter jejuni reveals hypervariable sequences. Nature 2000; 403:665-8; PMID:10688204; http://dx.doi.org/10.1038/35001088
30. Karlyshev AV, McCrossan MV, Wren BW. Demonstration of polysaccharide capsule in Campylobacter jejuni using electron microscopy. Infect Immun 2001; 69:5921-4; PMID:11500474; http://dx.doi.org/10.1128/IAI.69.9.5921-5924.2001
31. Penner JL, Hennessy JN. Passive hemagglutination technique for serotyping Campylobacter fetus subsp. jejuni on the basis of soluble heat-stable antigens. J Clin Microbiol 1980; 12:732-7; PMID:6796598
32. Bacon DJ, Szymanski CM, Burr DH, Silver RP, Alm RA, Guerry P. A phase-variable capsule is involved in virulence of Campylobacter jejuni 81-176. Mol Microbiol 2001; 40:769-77; PMID:11359581; http://dx.doi.org/10.1046/j.1365- 2958.2001.02431.x
33. Grant AJ, Coward C, Jones MA, Woodall CA, Barrow PA, Maskell DJ. Signature-tagged transposon mutagenesis studies demonstrate the dynamic nature of cecal colonization of 2-week-old chickens by Campylobacter jejuni. Appl Environ Microbiol 2005; 71:8031-41; PMID:16332783; http://dx.doi.org/10.1128/ AEM.71.12.8031-8041.2005
34. Maue AC, Mohawk KL, Giles DK, Poly F, Ewing CP, Jiao Y, Lee G, Ma Z, Monteiro MA, Hill CL, et al. The polysaccharide capsule of Campylobacter jejuni modulates the host immune response. Infect Immun 2013; 81:665-72; PMID:23250948; http://dx.doi.org/10.1128/IAI.01008-12
35. Bacon DJ, Szymanski CM, Burr DH, Silver RP, Alm RA, Guerry P. A phase-variable capsule is involved in virulence of Campylobacter jejuni 81-176. Mol Microbiol 2001; 40:769-77; PMID:11359581; http://dx.doi.org/10.1046/j.1365- 2958.2001.02431.x
36. Rose A, Kay E, Wren BW, Dallman MJ. The Campylobacter jejuni NCTC11168 capsule prevents excessive cytokine production by dendritic cells. Med Microbiol Immunol 2012; 201:137-44; PMID:21863342; http://dx.doi.org/10.1007/s00430-011- 0214-1
37. Black RE, Levine MM, Clements ML, Hughes TP, Blaser MJ. Experimental Campylobacter jejuni infection in humans. J Infect Dis 1988; 157:472-9; PMID:3343522; http://dx.doi.org/10.1093/infdis/157.3.472
38. Tribble DR, Baqar S, Scott DA, Oplinger ML, Trespalacios F, Rollins D, Walker RI, Clements JD, Walz S, Gibbs P, et al. Assessment of the duration of protection in Campylobacter jejuni experimental infection in humans. Infect Immun 2010; 78:1750-9; PMID:20086085; http://dx.doi.org/10.1128/IAI.01021-09
39. Guerry P, Szymanski CM, Prendergast MM, Hickey TE, Ewing CP, Pattarini DL, Moran AP. Phase variation of Campylobacter jejuni 81-176 lipooligosaccharide affects ganglioside mimicry and invasiveness in vitro. Infect Immun 2002; 70:787-93; PMID:11796612; http://dx.doi.org/10.1128/IAI.70.2.787-793.2002
40. Poly F, Read TD, Chen YH, Monteiro MA, Serichantalergs O, Pootong P, Bodhidatta L, Mason CJ, Rockabrand D, Baqar S, et al. Characterization of two Campylobacter jejuni strains for use in volunteer experimental-infection studies. Infect Immun 2008; 76:5655-67; PMID:18809665; http://dx.doi.org/10. 1128/IAI.00780-08
41. Tribble DR, Baqar S, Carmolli MP, Porter C, Pierce KK, Sadigh K, Guerry P, Larsson CJ, Rockabrand D, Ventone CH, et al. Campylobacter jejuni strain CG8421: a refined model for the study of Campylobacteriosis and evaluation of Campylobacter vaccines in human subjects. Clin Infect Dis 2009; 49:1512-9; PMID:19842970; http://dx.doi.org/10.1086/644622
42. Kirkpatrick BD, Lyon CE, Porter CK, Maue AC, Guerry P, Pierce KK, Carmolli MP, Riddle MS, Larsson CJ, Hawk D, et al. Lack of homologous protection against Campylobacter jejuni CG8421 in a human challenge model. Clin Infect Dis 2013; 57:1106-13; PMID:23840001; http://dx.doi.org/10.1093/cid/cit454
43. Kaech SM, Wherry EJ, Ahmed R. Effector and memory T-cell differentiation: implications for vaccine development. Nat Rev Immunol 2002; 2:251-62; PMID:12001996; http://dx.doi.org/10.1038/nri778
44. Griffin A, Baraho-Hassan D, McSorley SJ. Successful treatment of bacterial infection hinders development of acquired immunity. J Immunol 2009; 183:1263-70; PMID:19542362; http://dx.doi.org/10.4049/jimmunol.0900772
45. Tribble DR, Baqar S, Thompson SA. Development of a Human Vaccine. In: Nachamkin I, Szymanski CM, Blaser MJ, eds. Campylobacter. Washington D.C.: ASM Press, 2008:429-44.
46. Lesinski GB, Westerink MA. Vaccines against polysaccharide antigens. Curr Drug Targets Infect Disord 2001; 1:325-34; PMID:12455405; http://dx.doi.org/10. 2174/1568005014605964
47. Knuf M, Kowalzik F, Kieninger D. Comparative effects of carrier proteins on vaccine-induced immune response. Vaccine 2011; 29:4881-90; PMID:21549783; http://dx.doi.org/10.1016/j.vaccine.2011.04.053
48. Takahashi I, Nochi T, Yuki Y, Kiyono H. New horizon of mucosal immunity and vaccines. Curr Opin Immunol 2009; 21:352-8; PMID:19493665; http://dx.doi.org/10.1016/j.coi.2009.04.002
49. Passwell JH, Harlev E, Ashkenazi S, Chu C, Miron D, Ramon R, Farzan N, Shiloach J, Bryla DA, Majadly F, et al. Safety and immunogenicity of improved Shigella O-specific polysaccharide-protein conjugate vaccines in adults in Israel. Infect Immun 2001; 69:1351-7; PMID:11179298; http://dx.doi.org/10.1128/ IAI.69.3.1351-1357.2001
50. Cohen D, Ashkenazi S, Green MS, Gdalevich M, Robin G, Slepon R, Yavzori M, Orr N, Block C, Ashkenazi I, et al. Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults. Lancet 1997; 349:155-9; PMID:9111538; http://dx.doi.org/10.1016/S0140-6736(96)06255-1
51. Mond JJ, Vos Q, Lees A, Snapper CM. T cell independent antigens. Curr Opin Immunol 1995; 7:349-54; PMID:7546399; http://dx.doi.org/10.1016/0952- 7915(95)80109-X
52. Mond JJ, Lees A, Snapper CM. T cell-independent antigens type 2. Annu Rev Immunol 1995; 13:655-92; PMID:7612238; http://dx.doi.org/10.1146/annurev.iy.13. 040195.003255
53. Mosier DE, Mond JJ, Goldings EA. The ontogeny of thymic independent antibody responses in vitro in normal mice and mice with an X-linked B cell defect. J Immunol 1977; 119:1874-8; PMID:334975
54. Lesinski GB, Westerink MA. Novel vaccine strategies to T-independent antigens. J Microbiol Methods 2001; 47:135-49; PMID:11576678; http://dx.doi.org/10.1016/S0167-7012(01)00290-1
55. Rijkers GT, Sanders EA, Breukels MA, Zegers BJ. Infant B cell responses to polysaccharide determinants. Vaccine 1998; 16:1396-400; PMID:9711778; http://dx.doi.org/10.1016/S0264-410X(98)00098-X
56. Dintzis RZ, Okajima M, Middleton MH, Greene G, Dintzis HM. The immunogenicity of soluble haptenated polymers is determined by molecular mass and hapten valence. J Immunol 1989; 143:1239-44; PMID:2473123
57. Monteiro MA, Baqar S, Hall ER, Chen YH, Porter CK, Bentzel DE, Applebee L, Guerry P. Capsule polysaccharide conjugate vaccine against diarrheal disease caused by Campylobacter jejuni. Infect Immun 2009; 77:1128-36; PMID:19114545; http://dx.doi.org/10.1128/IAI.01056-08
58. McHeyzer-Williams LJ, McHeyzer-Williams MG. Antigen-specific memory B cell development. Annu Rev Immunol 2005; 23:487-513; PMID:15771579; http://dx.doi.org/10.1146/annurev.immunol.23.021704.115732
59. Crotty S, Ahmed R. Immunological memory in humans. Semin Immunol 2004; 16:197-203; PMID:15130504; http://dx.doi.org/10.1016/j.smim.2004.02.008
60. Jones FR, Baqar S, Gozalo A, Nunez G, Espinoza N, Reyes SM, Salazar M, Meza R, Porter CK, Walz SE. New World monkey Aotus nancymae as a model for Campylobacter jejuni infection and immunity. Infect Immun 2006; 74:790-3; PMID:16369042; http://dx.doi.org/10.1128/IAI.74.1.790-793.2006
61. Pike BL, Guerry P, Poly F. Pike BL, Guerry P, Poly F. Global Distribution of Campylobacter jejuni Penner Serotypes: A Systematic Review. PLoS One 2013; 8:e67375; PMID:23826280; http://dx.doi.org/10.1371/journal.pone.0067375
62. Poly F, Serichatalergs O, Schulman M, Ju J, Cates CN, Kanipes M, Mason C, Guerry P. Discrimination of major capsular types of Campylobacter jejuni by multiplex PCR. J Clin Microbiol 2011; 49:1750-7; PMID:21411576; http://dx.doi.org/10.1128/JCM.02348-10
63. Taylor DN, Echeverria P, Pitarangsi C, Seriwatana J, Bodhidatta L, Blaser MJ. Influence of strain characteristics and immunity on the epidemiology of Campylobacter infections in Thailand. J Clin Microbiol 1988; 26:863-8; PMID:3384911
64. Taylor DN, Perlman DM, Echeverria PD, Lexomboon U, Blaser MJ. Campylobacter immunity and quantitative excretion rates in Thai children. J Infect Dis 1993; 168:754-8; PMID:8354916; http://dx.doi.org/10.1093/infdis/168. 3.754
65. Blaser MJ, Black RE, Duncan DJ, Amer J. Campylobacter jejuni-specific serum antibodies are elevated in healthy Bangladeshi children. J Clin Microbiol 1985; 21:164-7; PMID:3972984
66. Blaser MJ, Taylor DN, Echeverria P. Immune response to Campylobacter jejuni in a rural community in Thailand. J Infect Dis 1986; 153:249-54; PMID:3944480; http://dx.doi.org/10.1093/infdis/153.2.249
67. Romero-Steiner S, Fernandez J, Biltoft C, Wohl ME, Sanchez J, Feris J, Balter S, Levine OS, Carlone GM. Functional antibody activity elicited by fractional doses of Haemophilus influenzae type b conjugate vaccine (polyribosylribitol phosphate-tetanus toxoid conjugate). Clin Diagn Lab Immunol 2001; 8:1115-9; PMID:11687449
68. Romero-Steiner S, Spear W, Brown N, Holder P, Hennessy T, Gomez De Leon P, Carlone GM. Measurement of serum bactericidal activity specific for Haemophilus influenzae type b by using a chromogenic and fluorescent metabolic indicator. Clin Diagn Lab Immunol 2004; 11:89-93; PMID:14715550
69. Frasch CE, Borrow R, Donnelly J. Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Vaccine 2009; 27(Suppl 2):B112-6; PMID:19464093; http://dx.doi.org/10.1016/j.vaccine.2009.04.065
70. Romero-Steiner S, Frasch CE, Carlone G, Fleck RA, Goldblatt D, Nahm MH. Use of opsonophagocytosis for serological evaluation of pneumococcal vaccines. Clin Vaccine Immunol 2006; 13:165-9; PMID:16467321; http://dx.doi.org/10.1128/ CVI.13.2.165-169.2006
71. Fleck RA, Romero-Steiner S, Nahm MH. Use of HL-60 cell line to measure opsonic capacity of pneumococcal antibodies. Clin Diagn Lab Immunol 2005; 12:19-27; PMID:15642980